Development and Evaluation of Buccoadhesive Controlled Release Tablets of Lercanidipine

Abstract

The purpose of this research was to develop and evaluate buccal mucoadhesive controlled release tablets of lercanidipine hydrochloride using polyethylene oxide and different viscosity grades of hydroxypropyl methylcellulose individually and in combination. Effect of polymer type, proportion and combination was studied on the drug release rate, release mechanism and mucoadhesive strength of the prepared formulations. Buccal mucoadhesive tablets were made by direct compression and were characterized for content uniformity, weight variation, friability, surface pH, thickness and mechanism of release. In order to estimate the relative enhancement in bioavailability one optimized formulation was evaluated in rabbits. Further, placebo tablets were also evaluated for acceptability in human subjects. Results indicated acceptable physical characteristics of designed tablets with good content uniformity and minimum weight variation. Drug release and mucoadhesive strength were found to depend upon polymer type, proportion and viscosity. The formulations prepared using poly ethylene oxide gave maximum mucoadhesion. The release mechanism of most formulations was found to be of anomalous non-Fickian type. In vivo studies of selected formulation in rabbits demonstrated significant enhancement in bioavailability of lercanidipine hydrochloride relative to orally administered drug. Moreover, in human acceptability studies of placebo formulations, the designed tablets adhered well to the buccal mucosa for more than 4 h without causing any discomfort. It may be concluded that the designed buccoadhesive controlled release tablets have the potential to overcome the disadvantage of poor and erratic oral bioavailability associated with the presently marketed formulations of lercanidipine hydrochloride.

Controlled release effervescent buccal discs of buspirone hydrochloride:in vitroandin vivoevaluation studies

“…In vitro drug release studies were performed using in-house modified USP type-I dissolution apparatus as reported earlier (Charde et al, 2008, Jaipal et al, 2013. Briefly, the method uses 50 mL capacity screw cap tubes arranged on a dissolution vessel using in-house designed aluminum holder.…”

Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system

“…Formulations were chosen, from each of the constructed phase diagram of nanoemulsifying region so obtained, such that amount of oil in each formulation should be able to dissolve 10 mg of drug easily as recommended dose of LER is 10 mg/day Charde et al [12].…”

Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability

“…Rabbits fasted for 24 h before the experiment and were divided into two groups, each having six animals. The selection of rabbits as animal model for the present study was based on previously published pharmacokinetic studies (31)(32)(33). The first group received orally the 10-mg reference tablets (Zyprexa® by Eli Lilly) and the second group received orally 10-mg CR test tablets of olanzapine.…”